ERBB2 and breast cancer: Although the incidence of brain metastasis in this BC subtype is not as high as that experienced by the more aggressive subtypes, such as triple-negative and HER-2-positive BC, there was an interest in evaluating the activity of CDK4/6 inhibitors in central nervous system (CNS) metastasis [42].